Cybin D/B/A Helus Pharma
$5.61
▲
2.61%
2026-04-21 07:16:03
cybin.com
NGM: HELP
Explore Cybin D/B/A Helus Pharma stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.92 M
Current Price
$5.61
52W High / Low
$12.7 / $5.9
Stock P/E
—
Book Value
$5.49
Dividend Yield
—
ROCE
-60.35%
ROE
-55.89%
Face Value
—
EPS
$-4.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
50
Beta
1.04
Debt / Equity
0
Current Ratio
13.78
Quick Ratio
7.75
Forward P/E
-1.64
Price / Sales
—
Enterprise Value
$685.96 M
EV / EBITDA
-5.75
EV / Revenue
—
Rating
None
Target Price
$48.49
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 2. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 3. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 4. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 5. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 6. | KALA BIO, Inc. | $0.2 | — | $185.9 M | — | -88.86% | -388.29% | $20.6 / $0.15 | $-1.17 |
| 7. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -41.21 M | -28.89 M | -24.62 M | -33.27 M | -22.39 M | — |
| Net Profit | -42.67 M | -33.72 M | -24.61 M | -30.58 M | -7.54 M | — |
| EPS in Rs | -0.86 | -0.68 | -0.49 | -0.61 | -0.15 | -2.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -143.15 M | -78.84 M | -51.52 M | -63.84 M |
| Net Profit | -113.14 M | -78.08 M | -47.49 M | -67.63 M |
| EPS in Rs | -2.27 | -1.56 | -0.95 | -1.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 258.62 M | 302.02 M | 53.9 M | 84.06 M |
| Total Liabilities | 21.42 M | 10.1 M | 5.66 M | 7.91 M |
| Equity | 237.2 M | 291.93 M | 48.23 M | 76.16 M |
| Current Assets | 165.97 M | 218.54 M | 23.18 M | 58.35 M |
| Current Liabilities | 21.42 M | 10.1 M | 5.66 M | 7.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -101.3 M | -68.91 M | -47.43 M | -45.21 M |
| Investing CF | -1.97 M | 6.92 M | -3.31 M | -0.77 M |
| Financing CF | 20.2 M | 254.51 M | 13.56 M | 35.78 M |
| Free CF | -103.27 M | -69.62 M | -50.74 M | -45.73 M |
| Capex | -1.97 M | -0.71 M | -3.31 M | -0.52 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -44.9% | -64.41% | 29.78% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-19 | 1:0.0263158 |